Skip to main content

Table 3 Summary of Tsc2-/- Subcutaneous Tumor Data (Vincristine, Asparaginase, Sunitinib, and Bevacizumab)

From: Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors

 

Untreated

Rapamycin

Vincristine

Combination Vincristine plus Rapamycin

Asparaginase

Combination Asparaginase plus Rapamycin

Sunitinib

Combination Sunitinib plus Rapamycin

Bevacizumab

Combination Bevacizumab plus Rapamycin

Number of mice (n)

8

8

8

8

8

8

8

8

8

8

Median Survival (days)

31

84.5

26

77

39.5

71

39

80

38.5

60

P value (survival)

-

<0.0001*

NS*

NS#

0.0101*

NS#

0.0193*

NS#

0.0131*

NS#

Day 23, average tumor volume ± SEM (mm3)

1557 ± 260

352 ± 149

2289 ± 242

-

-

-

-

-

-

-

P Value (Day 23)

-

0.0016*

NS*

-

-

-

-

-

-

-

Day 30, average tumor volume ± SEM (mm3)

2618 ± 187

545 ± 212

-

330 ± 101

1978 ± 167

441 ± 97

1886 ± 287

545 ± 114

1233 ± 366

813 ± 449

P Value (Day 30)

-

0.0001*

-

-

0.0405*

-

NS*

-

0.0172*

-

Day 65, average tumor volume ± SEM (mm3)

-

1349 ± 302

-

2050 ± 384

-

1570 ± 378

-

1643 ± 246

-

1652 ± 557

P Value (Day 65)

-

-

-

NS#

-

NS#

-

NS#

-

NS#

Rapamycin (IP, 3 days per week)

-

8 mg/kg, 3 days per week

-

8 mg/kg, 3 days per week

-

8 mg/kg, 3 days per week

-

8 mg/kg, 3 days per week

-

8 mg/kg, 3 days per week

Vincristine (IP, weekly × 4 weeks)

-

-

0.5 mg/kg, weekly × 4 weeks

0.5 mg/kg, weekly × 4 weeks

-

-

-

-

-

-

Asparaginase (IP, Mon, Thurs × 4 weeks)

-

-

-

-

2 IU/g, Mon, Thurs × 4 weeks

2 IU/g, Mon, Thurs × 4 weeks

-

-

-

-

Sunitinib (Gavage, Mon-Fri)

-

-

  

-

-

80 mg/kg, Mon- Fri

80 mg/kg, Mon- Fri

-

-

Bevacizumab (IP, once/2 weeks)

-

-

-

-

-

-

-

-

5 mg/kg, once/2 weeks

5 mg/kg, once/2 weeks

  1. * compared to untreated
  2. # compared to rapamycin treated
  3. NS, not significant
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us